A phase 1/2 first in human study of ADI-270, an armored allogeneic anti-CD70 chimeric antigen receptor γδ T cell therapy, in relapsed or refractory (R/R) clear cell renal cell carcinoma (ccRCC).

Authors: Sumanta Kumar Pal, Benjamin Garmezy, Helen Budworth, Xiaoyan Du, Shon Green, Kevin Nishimoto, Jackie Kennedy-Wilde, Blake T. Aftab, Julia D. Maltzman, Gregory Sumpao Vosganian, Brian I. Rini

Published: 2025-05-28

DOI: 10.1200/jco.2025.43.16_suppl.tps4613

Source: Full article

---

Abstract

TPS4613